...
首页> 外文期刊>Journal of Medicinal Chemistry >Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor
【24h】

Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor

机译:基于多功能肽支架的特定丝氨酸蛋白酶抑制剂的设计:尿激酶抑制剂向血浆激肽释放酶抑制剂的转化。

获取原文
获取原文并翻译 | 示例
           

摘要

All serine proteases hydrolyze peptide bonds by the same basic mechanism and have very similar active sites, in spite of the fact that individual proteases have different physiological functions. We here report a strategy for designing high-affinity and high-specificity serine protease inhibitors using a versatile peptide scaffold, a 10-mer. peptide, mupain-1 (CPAYSRYLDC). Mupain-1 was previously reported as a specific inhibitor of murine urokinase-type plasminogen activator (K-i = 0.55 mu M) without measurable affinity to plasma kallikrein (K-i > 1000 mu M). X-ray crystal structure analysis showed that the new peptide was able to adapt a new set of enzyme surface interactions by a slightly changed backbone conformation. Thus, with an appropriate re-engineering, mupain-1 can be redesigned to specific inhibitors of other serine proteases.
机译:尽管各个蛋白酶具有不同的生理功能,但所有丝氨酸蛋白酶均通过相同的基本机理水解肽键并具有非常相似的活性位点。我们在这里报告了一种使用多功能肽支架(10-mer)设计高亲和力和高特异性丝氨酸蛋白酶抑制剂的策略。肽mupain-1(CPAYSRYLDC)。以前有报道称Mupain-1是一种鼠尿激酶型纤溶酶原激活剂的特异性抑制剂(K-i = 0.55μM),对血浆激肽释放酶(K-i> 1000μM)没有亲和力。 X射线晶体结构分析表明,新肽能够通过稍微改变主链构象来适应新的一组酶表面相互作用。因此,通过适当的改造,可以将mupain-1重新设计为其他丝氨酸蛋白酶的特异性抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号